Product Launched Software & Services NSE: TCS ·

TCS Launches Agentic AI Platform TCS ADD AgentHub to Transform Drug Development

NSE Filing 3 min read 16 views
TCS Launches Agentic AI Platform TCS ADD AgentHub to Transform Drug Development

Tata Consultancy Services Limited — Product Launched · TCS

Efficiency Gain

40%

Clinical Data Mgmt

Market Cap

₹8,42,580 Cr

Large Cap

Revenue TTM

₹2,75,859 Cr

IT Services

Day RSI

52.84

Neutral Zone

! Key Highlights

  • Platform demonstrates up to 40% efficiency gains in clinical data management activities
  • Achieves 30% reduction in clinical study build effort through metadata-driven automation
  • Delivers up to 30% cost savings in end-to-end safety case processing functions
  • Reduces quality control effort by as much as 50% for AI-powered safety agents
  • Employs a Human + AI Operating Model where humans retain final decision-making authority

Tata Consultancy Services has launched TCS ADD AgentHub, an enterprise-ready agentic AI platform designed to accelerate drug development and pharmacovigilance. The platform integrates autonomous AI agents into clinical workflows to enhance research productivity while maintaining strict regulatory compliance.

The Product — What It Is

TCS ADD AgentHub is an enterprise-ready platform designed to scale agentic AI across the pharmaceutical research and development value chain. Built on the proprietary TCS ADD framework, it provides a structured environment where AI agents operate with defined roles, clear oversight, and built-in auditability. The platform addresses specific challenges in highly regulated environments, such as fragmented data systems and increasing regulatory complexity.

It supports a wide array of workflows including clinical development, pharmacovigilance, and literature analysis. By deploying an evolving catalog of specialized AI workers, pharmaceutical companies can automate routine tasks like data entry and coding while accelerating complex processes like study design and protocol digitization.

Commercial Opportunity

  • Pharma companies can achieve up to 30% cost savings in end-to-end safety case processing using the platform
  • Metadata-driven automation within the hub reduces clinical study build efforts by 30%
  • AI-powered safety agents contribute to a 50% reduction in quality control efforts for R&D teams
  • Rapid integration capabilities allow for streamlined deployment across clinical workflows with minimal implementation effort

Strategic Fit

This launch aligns with the company’s AI-first culture and its objective to become the world's largest AI-led technology services provider. By leveraging its proprietary cognitive intelligence suite, the company is moving towards autonomous enterprise functions where AI workforces operate alongside human teams. This specialized platform deepens the company's footprint in the Life Sciences and Healthcare sector, a key vertical that contributed to its consolidated revenues exceeding 30 billion dollars in the 2026 fiscal year.

The Human + AI operating model ensures that pharmaceutical clients can scale AI adoption without compromising the governance and decision-making responsibilities required by global health regulators.

Business Overview

Tata Consultancy Services is a global leader in IT services, consulting, and business solutions, serving industry-leading organizations since 1968. Rooted in the heritage of the Tata Group, the company operates a massive network of 194 service delivery centers across 56 countries. It has established a significant presence in the Life Sciences and Healthcare vertical, focusing on digital transformation, infrastructure, and intelligence.

The company continues to invest in its proprietary TCS ADD suite to enable predictive and secure digital ecosystems for global pharmaceutical clients, helping them emerge as perpetually adaptive enterprises in an evolving technological landscape.

Tata Consultancy Services Limited — Financial Snapshot

BSE: 532540 · NSE: TCS · Software & Services

Current Market Price ₹2328.8 per share
Market Capitalisation ₹8.43L Cr BSE Listed
Revenue (Annual) ₹2.67L Cr Operating
Net Profit (Annual) ₹49,210.00 Cr Consolidated
P/E Ratio (TTM) 16.92× Sector: 22.94×
Promoter Holding 71.77% 0.00% QoQ
FII Holding 9.07% Current Qtr

"TCS ADD™ AgentHub, is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment."

— Debashis Ghosh, President, Lifesciences and Healthcare, TCS

Source Verified

Exchange filing by Tata Consultancy Services Limited announcing the launch of TCS ADD AgentHub for drug development. Financial metrics from Trendlyne.

View Filing